Aarti Pharmalabs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 8, 2026
- Posted by: Harsh Piplani
- Category: Results
Aarti Pharmalabs share price Rs 867.00 on 8 September 2026, up 0.50%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 76.14 crore. Q2 FY26 base a profit of Rs 27.92 crore.
Quick Answer
The Aarti Pharmalabs Q2 results date for FY27 is not confirmed, and Aarti Pharmalabs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 418.38 crore in revenue and a profit of Rs 27.92 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Aarti Pharmalabs Q2 results FY27 announcement is the next scheduled earnings event for Aarti Pharmalabs Ltd., a pharmaceutical intermediates and active ingredients maker with a contract manufacturing business and a xanthine derivatives franchise. The stock traded at Rs 867.00 on the NSE on 8 September 2026, up 0.50% from the previous close of Rs 862.65, about 8.4% below its 52-week high of Rs 946.10 and 48.2% above its 52-week low of Rs 585.00.
What makes the Aarti Pharmalabs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 418.38 crore of revenue and a profit of Rs 27.92 crore, while the most recent quarter on record, Q1 FY27, produced Rs 536.25 crore and a profit of Rs 76.14 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Aarti Pharmalabs Q2 Results FY27 Date?
The Aarti Pharmalabs Q2 results date for FY27 is not confirmed. As of 8 September 2026, Aarti Pharmalabs Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Aarti Pharmalabs Q2 results date becomes public through that filing rather than through any advance announcement.
The Aarti Pharmalabs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Aarti Pharmalabs.
Aarti Pharmalabs Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Aarti Pharmalabs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Aarti Pharmalabs. The Aarti Pharmalabs Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is the margin gap against the base. Operating margin was 26.87% in Q1 FY27 against 17.72% in the September 2025 quarter, and that nine point spread is the reason profit more than doubled while revenue rose by less than a third.
The second is the September 2025 profit base of Rs 27.92 crore, the weakest of the last five quarters. A soft base makes the year-on-year percentage look large, so the rupee figure is the more honest measure of progress.
The third is contract manufacturing order flow. Revenue from development and supply agreements arrives in batches, and the split between the xanthine franchise and contract work explains most of the quarter-to-quarter margin movement.
Check Aarti Pharmalabs Ltd. Live Fundamentals on the Univest Screener
Aarti Pharmalabs Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Aarti Pharmalabs Ltd. reported revenue of Rs 536.25 crore in Q1 FY27, up 38.28% from Rs 387.79 crore in Q1 FY26, and a profit of Rs 76.14 crore at the net level, up 53.82% from Rs 49.50 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 9.22% over the March 2026 quarter figure of Rs 590.69 crore, and net profit was up 24.57% from Rs 61.12 crore in Q4 FY26. Operating margin stood at 26.87% in Q1 FY27 against 17.72% in the September 2025 quarter, which is the comparison the Aarti Pharmalabs Q2 results print will be read against.
Q2 FY26 Base: The Comparison Aarti Pharmalabs Q2 Results FY27 Must Beat
Aarti Pharmalabs Ltd. reported revenue of Rs 418.38 crore and a profit of Rs 27.92 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Aarti Pharmalabs Q2 results preview.
Net profit in that base quarter was below the Rs 76.14 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 418.38 crore sits below the Rs 536.25 crore of the June 2026 quarter, which frames how much sequential movement the Aarti Pharmalabs Q2 results print needs to show growth.
Aarti Pharmalabs Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 418.38 | 27.92 |
| Q3 FY26 (Dec 2025) | 431.90 | 47.96 |
| Q4 FY26 (Mar 2026) | 590.69 | 61.12 |
| Q1 FY27 (Jun 2026) | 536.25 | 76.14 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Aarti Pharmalabs Q2 results preview uses.
Revenue across those four quarters ranged from Rs 418.38 crore to Rs 590.69 crore, and net profit from Rs 27.92 crore to Rs 76.14 crore. That spread is the honest context for the Aarti Pharmalabs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Aarti Pharmalabs Q2 Results FY27
The Aarti Pharmalabs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Aarti Pharmalabs has already reported.
Xanthine Derivatives and Product Mix
The xanthine derivatives business carries different economics from generic intermediates, so the revenue mix decides margin more than volume does. Segment commentary in the filing is where that shows up.
Contract Manufacturing Pipeline
Development and supply contracts for global pharmaceutical customers arrive unevenly. A milestone or a commercial supply start can lift a single quarter, which is why the March 2026 revenue of Rs 590.69 crore sat well above the run rate.
Valuation in Line With the Sector
Aarti Pharmalabs trades at a price-to-earnings ratio of 36.65 against a sector average of 37.70, on a return on equity of 8.22% and a debt-to-equity ratio of 0.36. The stock sits well above both moving averages after a strong run.
Aarti Pharmalabs Q2 Results FY27: Share Price and Valuation Going Into the Print
Aarti Pharmalabs share price today is Rs 867.00 on the NSE, up Rs 4.35 or 0.50% from the previous close of Rs 862.65 on 8 September 2026, ahead of the Aarti Pharmalabs Q2 results announcement.
| Metric | Value (8 September 2026) |
|---|---|
| NSE Symbol | AARTIPHARM |
| Current Market Price | Rs 867.00 |
| 52-Week High | Rs 946.10 |
| 52-Week Low | Rs 585.00 |
| Market Capitalisation | Rs 7,814 crore |
| PE Ratio | 36.65 |
| Sector PE | 37.70 |
| PB Ratio | 3.68 |
| EPS (TTM) | Rs 23.51 |
| Book Value per Share | Rs 234.30 |
| Debt to Equity | 0.36 |
| Return on Equity | 8.22% |
| 50-Day Moving Average | Rs 762.81 |
| 200-Day Moving Average | Rs 721.23 |
| RSI (14) | 61.72 |
The stock trades above both its 50-day average of Rs 762.81 and its 200-day average of Rs 721.23, with a 14-day RSI of 61.72. None of this is a view on where the shares go once the Aarti Pharmalabs Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Aarti Pharmalabs Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Aarti Pharmalabs Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Aarti Pharmalabs Q2 results print in proportion.
- Revenue against the Rs 418.38 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 27.92 crore in that same quarter
- Operating margin against 26.87% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Aarti Pharmalabs Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Aarti Pharmalabs Q2 Results FY27
The Aarti Pharmalabs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Aarti Pharmalabs Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Aarti Pharmalabs Q2 results FY27 print faces a base of Rs 418.38 crore in revenue and a profit of Rs 27.92 crore, with the most recent quarter having delivered Rs 536.25 crore and a profit of Rs 76.14 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Aarti Pharmalabs, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Aarti Pharmalabs Q2 Results FY27
What is the Aarti Pharmalabs Q2 results date for FY27?
Ans. The Aarti Pharmalabs Q2 results date for FY27 is not confirmed. Aarti Pharmalabs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Aarti Pharmalabs Q2 results 2026 cover?
Ans. The Aarti Pharmalabs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Aarti Pharmalabs Ltd. reports revenue, operating profit and net profit for that period, and the Aarti Pharmalabs Q2 results filing also carries the notes to the accounts.
What were the Aarti Pharmalabs Q1 FY27 results?
Ans. Aarti Pharmalabs Ltd. reported revenue of Rs 536.25 crore in Q1 FY27 and a profit of Rs 76.14 crore at the net level. Revenue was up 38.28% versus Q1 FY26 and net profit was up 53.82% from Rs 49.50 crore in Q1 FY26.
What were Aarti Pharmalabs Q2 FY26 results in the September 2025 quarter?
Ans. Aarti Pharmalabs Ltd. reported revenue of Rs 418.38 crore and a profit of Rs 27.92 crore in Q2 FY26. Operating margin was 17.72%. Those figures form the base for the Aarti Pharmalabs Q2 results FY27 comparison.
What are the main Aarti Pharmalabs Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Aarti Pharmalabs Q2 results expectations centre on revenue against the Rs 418.38 crore base, net profit against a profit of Rs 27.92 crore, operating margin against 26.87% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Aarti Pharmalabs share price today ahead of the Q2 earnings?
Ans. Aarti Pharmalabs share price is Rs 867.00 on the NSE as of 8 September 2026, up 0.50% from Rs 862.65. The stock is about 8.4% below its 52-week high of Rs 946.10 and 48.2% above its 52-week low of Rs 585.00, at a market capitalisation of Rs 7,814 crore.
Is Aarti Pharmalabs a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Aarti Pharmalabs Ltd.. The stock trades at a price-to-book ratio of 3.68 with a return on equity of 8.22%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
